Literature DB >> 15634943

Serotonergic neurotoxic metabolites of ecstasy identified in rat brain.

Douglas C Jones1, Christine Duvauchelle, Aiko Ikegami, Christopher M Olsen, Serrine S Lau, Rafael de la Torre, Terrence J Monks.   

Abstract

The selective serotonergic neurotoxicity of 3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) depends on their systemic metabolism. We have recently shown that inhibition of brain endothelial cell gamma-glutamyl transpeptidase (gamma-GT) potentiates the neurotoxicity of both MDMA and MDA, indicating that metabolites that are substrates for this enzyme contribute to the neurotoxicity. Consistent with this view, glutathione (GSH) and N-acetylcysteine conjugates of alpha-methyl dopamine (alpha-MeDA) are selective neurotoxicants. However, neurotoxic metabolites of MDMA or MDA have yet to be identified in brain. Using in vivo microdialysis coupled to liquid chromatography-tandem mass spectroscopy and a high-performance liquid chromatography-coulometric electrode array system, we now show that GSH and N-acetylcysteine conjugates of N-methyl-alpha-MeDA are present in the striatum of rats administered MDMA by subcutaneous injection. Moreover, inhibition of gamma-GT with acivicin increases the concentration of GSH and N-acetylcysteine conjugates of N-methyl-alpha-MeDA in brain dialysate, and there is a direct correlation between the concentrations of metabolites in dialysate and the extent of neurotoxicity, measured by decreases in serotonin (5-HT) and 5-hydroxyindole acetic (5-HIAA) levels. Importantly, the effects of acivicin are independent of MDMA-induced hyperthermia, since acivicin-mediated potentiation of MDMA neurotoxicity occurs in the context of acivicin-mediated decreases in body temperature. Finally, we have synthesized 5-(N-acetylcystein-S-yl)-N-methyl-alpha-MeDA and established that it is a relatively potent serotonergic neurotoxicant. Together, the data support the contention that MDMA-mediated serotonergic neurotoxicity is mediated by the systemic formation of GSH and N-acetylcysteine conjugates of N-methyl-alpha-MeDA (and alpha-MeDA). The mechanisms by which such metabolites access the brain and produce selective serotonergic neurotoxicity remain to be determined.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15634943     DOI: 10.1124/jpet.104.077628

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  31 in total

1.  In vitro metabolism of 3,4-methylenedioxymethamphetamine in human hepatocytes.

Authors:  Corinne Ramaley; Susan C Leonard; Jeffrey D Miller; Denita Takesha-Mashia Wilson; Sai Y Chang; Qingyu Chen; Feng Li; Chengan Du
Journal:  J Anal Toxicol       Date:  2014-03-28       Impact factor: 3.367

2.  L-tyrosine contributes to (+)-3,4-methylenedioxymethamphetamine-induced serotonin depletions.

Authors:  Joseph M Breier; Michael G Bankson; Bryan K Yamamoto
Journal:  J Neurosci       Date:  2006-01-04       Impact factor: 6.167

3.  MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers.

Authors:  Rafael de la Torre; Magí Farré; Brian O Mathúna; Pere N Roset; Neus Pizarro; Mireia Segura; Marta Torrens; Jordi Ortuño; Mitona Pujadas; Jordi Camí
Journal:  Eur J Clin Pharmacol       Date:  2005-07-23       Impact factor: 2.953

Review 4.  A developmental comparison of the neurobehavioral effects of ecstasy (MDMA).

Authors:  Brian J Piper
Journal:  Neurotoxicol Teratol       Date:  2006-10-20       Impact factor: 3.763

Review 5.  Amphetamine toxicities: classical and emerging mechanisms.

Authors:  Bryan K Yamamoto; Anna Moszczynska; Gary A Gudelsky
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

6.  Concurrent Inhibition of Vesicular Monoamine Transporter 2 Does Not Protect Against 3,4-Methylenedioxymethamphetamine (Ecstasy) Induced Neurotoxicity.

Authors:  Aram B Cholanians; Andy V Phan; Serrine S Lau; Terrence J Monks
Journal:  Toxicol Sci       Date:  2019-07-01       Impact factor: 4.849

7.  Attenuation of ecstasy-induced neurotoxicity by N-acetylcysteine.

Authors:  Sara Soleimani Asl; Bita Saifi; Abolhasan Sakhaie; Somayeh Zargooshnia; Mehdi Mehdizadeh
Journal:  Metab Brain Dis       Date:  2014-08-06       Impact factor: 3.584

8.  Glial cell response to 3,4-(+/-)-methylenedioxymethamphetamine and its metabolites.

Authors:  Joseph M Herndon; Aram B Cholanians; Serrine S Lau; Terrence J Monks
Journal:  Toxicol Sci       Date:  2013-12-03       Impact factor: 4.849

9.  Further studies on the role of metabolites in (+/-)-3,4-methylenedioxymethamphetamine-induced serotonergic neurotoxicity.

Authors:  Melanie Mueller; Jie Yuan; Anne Felim; Anne Neudörffer; Frank T Peters; Hans H Maurer; Una D McCann; Martine Largeron; George A Ricaurte
Journal:  Drug Metab Dispos       Date:  2009-07-23       Impact factor: 3.922

10.  Mechanism of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-mediated mitochondrial dysfunction in rat liver.

Authors:  Kwan-Hoon Moon; Vijay V Upreti; Li-Rong Yu; Insong J Lee; Xiaoying Ye; Natalie D Eddington; Timothy D Veenstra; Byoung-Joon Song
Journal:  Proteomics       Date:  2008-09       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.